Cytochrome P450 Drug Interactions Within the HMG-CoA Reductase Inhibitor ClassAre They Clinically Relevant?

被引:0
|
作者
Jennifer Martin
Henry Krum
机构
[1] Monash Medical School/Alfred Hospital,Clinical Pharmacology Unit
[2] Monash University/ Alfred Hospital,NHMRC Centre of Clinical Research Excellence in Therapeutics
[3] Prahran,undefined
来源
Drug Safety | 2003年 / 26卷
关键词
Simvastatin; Atorvastatin; Itraconazole; Pravastatin; Lovastatin;
D O I
暂无
中图分类号
学科分类号
摘要
The present review outlines the clinical relevance of pharmacokinetic drug interactions within the HMG-CoA reductase inhibitor class. These interactions can result in markedly increased or decreased plasma concentrations of some drugs within this class. However, the relationship between altered plasma concentrations and adverse effects or toxicity may not be linear. It is likely that other variables affect this concentration-effect relationship including: rapid changes in the concentration, concomitant lipid-lowering therapy or host genetic factors that code for different forms or amounts of metabolising enzymes and drug receptors.
引用
收藏
页码:13 / 21
页数:8
相关论文
共 18 条
  • [1] Genetic polymorphisms in cytochrome P450 enzymes: Effect on efficacy and tolerability of HMG-CoA reductase inhibitors
    Vermes A.
    Vermes I.
    American Journal of Cardiovascular Drugs, 2004, 4 (4) : 247 - 255
  • [2] Pharmacokinetic-Pharmacodynamic Drug Interactions with HMG-CoA Reductase Inhibitors
    David Williams
    John Feely
    Clinical Pharmacokinetics, 2002, 41 : 343 - 370
  • [3] Drug–Drug Interactions Between HMG-CoA Reductase Inhibitors (Statins) and Antiviral Protease Inhibitors
    Benoit Chauvin
    Sylvain Drouot
    Aurélie Barrail-Tran
    Anne-Marie Taburet
    Clinical Pharmacokinetics, 2013, 52 : 815 - 831
  • [4] Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy
    Rätz Bravo A.E.
    Tchambaz L.
    Krähenbühl-Melcher A.
    Hess L.
    Schlienger R.G.
    Krähenbühl S.
    Drug Safety, 2005, 28 (3) : 263 - 275
  • [6] Use of diagnostic cluster methodology for therapeutic costing and drug surveillance of HMG-CoA reductase-inhibitor therapy
    Bottorff, MB
    Yenkowsky, JP
    Cave, DG
    CLINICAL THERAPEUTICS, 1999, 21 (01) : 218 - 235
  • [7] Usefulness of HMG-CoA reductase inhibitor in Japanese hyperlipidemic women within seven years of menopause
    Ohta, H
    Masuda, A
    Fuyuki, T
    Sugimoto, I
    Suda, Y
    Makita, K
    Takamatsu, K
    Horiguchi, F
    Nozawa, S
    HORMONE RESEARCH, 2000, 53 (03) : 120 - 124
  • [8] Cytochrome P450 drug interactions with statin therapy
    Goh, Ivanna Xin Wei
    How, Choon How
    Tavintharan, Subramaniam
    SINGAPORE MEDICAL JOURNAL, 2013, 54 (03) : 131 - 135
  • [9] PHARMACOKINETIC DRUG INTERACTIONS BETWEEN HMG-COA REDUCTASE INHIBITORS PITAVASTATIN WITH CONCOMITANTLY USED TICAGRELOR
    Siddiqui, M. A. Hakeem
    Roshan, S.
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, 2020, 11 (06): : 2801 - 2806
  • [10] HMG-CoA Reductase Inhibitor Statins Activate the Transcriptional Activity of p53 by Regulating the Expression of TAZ
    Miyajima, Chiharu
    Hayakawa, Yurika
    Inoue, Yasumichi
    Nagasaka, Mai
    Hayashi, Hidetoshi
    PHARMACEUTICALS, 2022, 15 (08)